<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20145">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088411</url>
  </required_header>
  <id_info>
    <org_study_id>MU-699412</org_study_id>
    <nct_id>NCT02088411</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults</brief_title>
  <official_title>The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: a Randomized, Double-blind, Placebo-controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Innovations</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mucos Pharma GmbH, Oberhaching, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Innovations</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, double-blind, placebo-controlled, comparator-controlled trial
      was to evaluate the safety and efficacy of an enzyme combination, as WobenzymÂ®, in adults
      with moderate-to-severe osteoarthritis (OA) of the knee.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">November 2001</completion_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Lequesne Functional Index</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-assessment of the affected knee joint by physician interview using the Lequesne Functional Index (providing an estimate of the degree of pain associated with the affected joint, the maximum distance talked, and activities of daily living).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Index version 3.0 subscale for pain (WOMAC-A)</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Index version 3.0 subscale for joint stiffness (WOMAC-B)</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Index version 3.0 subscale for joint function (WOMAC-C)</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paracetamol Consumption</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of paracetamol tablets consumed during the study by subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indices of systemic inflammation</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Erythrocyte sedimentation rates at 1 and 2 hours and serum concentration of C-reactive protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Through baseline to 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any complications throughout study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Wobenzym</condition>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Diclofenac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wobenzym</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <arm_group_label>Diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Wobenzym</intervention_name>
    <arm_group_label>Wobenzym</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Knee osteoarthritis confirmed by radiography or tomography

          -  Lequesne Functional Index score of 10-14

          -  WOMAC-A pain subscale score greater than or equal to 25

        Exclusion Criteria:

          -  History of knee trauma

          -  History of joint infection

          -  History of joint surgery

          -  History of intra-articular injection (viscotherapy)

          -  History of gastrointestinal diseases

          -  Use of corticosteroids

          -  Use of COX-II inhibitors

          -  Use of glucosamine/chondroitin

          -  Known sensitivity to paracetamol

          -  Known sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Known sensitivity to oral enzymes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mucos Pharma GmbH &amp; Co</name>
      <address>
        <city>Oberhaching</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>March 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Wobenzym</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
